SYK|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $3.59 | - | - |
| Q2'26 | $3.49 | $3.69 | +5.8% |
| Q1'26 | $2.98 | $2.60 | -12.9% |
| Q4'25 | $4.44 | $4.47 | +0.7% |
| Q3'25 | $3.13 | $3.19 | +1.9% |
| Q2'25 | $3.07 | $3.13 | +1.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $6.7B | - | - |
| Q2'26 | $6.6B | $6.6B | -0.9% |
| Q1'26 | $6.3B | $6.0B | -4.9% |
| Q4'25 | $7.2B | $7.2B | -0.3% |
| Q3'25 | - | $6.1B | - |
| Q2'25 | - | $6.0B | - |
SYK|Monthly Returns
Market Data
SYK Stock Snapshot
- Market cap
- 109.41B
- P/E ratio
- 29.3
- Day range
- $281.70 – $283.52
- News sentiment
- 46/100 · Neutral
- Analyst target
- $376.28 (+32.7%)
- Consensus
- Buy · 36 analysts
The trend on SYK is bearish, and the indicator set is confirming it rather than diverging. In Healthcare, names this size usually take direction from sector flows before company-level news.
Reverse DCF
What growth is priced into SYK?
At today's price, Stryker Corporation needs to grow free cash flow about 10.0% a year for the next 10 years to justify its valuation at a 7.57% cost of capital. Over its actual history it has compounded free cash flow at 7.3% a year, so the market is asking for 2.6 percentage points above its own delivered rate. On that basis SYK looks priced roughly in line with its own growth record.
- Implied FCF growth
- 10.0%
- Historical FCF CAGR
- 7.3%
- Growth gap
- +2.6 pts
- Verdict
- FAIR
- Discount rate (WACC)
- 7.57%
- Beta
- 0.67
Behaviour On Record
What SYK's own history says about today's numbers
- Realized volatility (21d)
- 39.8% 95th pct
- Below its peak
- -29.4%
- vs 200-day average
- -15.3%
- Up days (1y)
- 48%
Stryker Corporation is currently running 39.8% annualised volatility over the last 21 sessions. Measured against SYK's own 13 years of daily returns rather than a market-wide average, that is the 95th percentile — an extreme by its own standards, against a typical reading of 19.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
SYK is trading -29.4% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -14.2%, and the deepest was -42.5% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits -15.3% from its 200-day moving average. Against every other day in its history, that gap ranks at the 2nd percentile — a narrower gap than it typically runs. Over the past year SYK closed higher on 48% of sessions, and it is currently 2 sessions into a rising streak.
On September specifically: over 13 years of records, SYK finished the month higher 5 of 13 times, with a median return of -2.0% and an average of -1.0%. Its strongest month historically has been January at +4.2% on average, its weakest March at -1.2%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: SYK has opened more than 2% away from the prior close in 88 of 3,267 sessions (2.7% of the time), with the largest gaps running +7.0% and -7.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, SYK moved an average of 2.6% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.9% and a largest of -6.0%.
All figures computed from 3,268 daily closes between 2013-09-16 and 2026-09-14, split-adjusted, recomputed daily. Percentiles are against SYK's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of SYK's sector?
Stryker Corporation sits in the Health Care sector, currently ranked 3rd of 11 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, SYK ranks 12th of 15 tracked industries, lagging.
- Sector rank
- #3 of 11
- Sector state
- Leading
- Sector rotation score
- 80
- Industry rank
- #12 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on SYK?
Citigroup most recently reiterated its rating on Stryker Corporation to Buy on Sep 10, 2026 with a price target of $360 (from $399). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.
- Latest action
- Citigroup — Buy
- 90-day upgrades
- 0
- 90-day downgrades
- 1
- Net rating momentum
- -1
SYK Competitive Positioning
- SYKyou're hereStryker Corporation$109.4B+1.26%
- ABTAbbott Laboratories$179.8B+1.03%
- EWEdwards Lifesciences Corporation$49.2B0.00%
- DXCMDexCom, Inc.$31.8B+0.15%
- STESTERIS plc$20.8B+0.02%
- ZBHZimmer Biomet Holdings, Inc.$17.8B+0.79%
